CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC (CELZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.11+4.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CELZ
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue efforts to control negative cash flow and reduce operating losses to improve financial stability.
Stated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$1.95M in 2025-Q4 to -$1.56M in 2026-Q2, with cash from operations also negative each quarter (e.g., -$1.47M in 2026-Q2). The trajectory shows persistent operating losses and negative cash flow, indicating limited progress on improving financial stability.
“Operating income was negative $1.56M and cash from operations negative $1.47M.”
“Operating income was negative $1.46M and cash from operations negative $1.32M.”
“Operating income was negative $1.95M and cash from operations negative $1.94M.”
“Operating income was negative $1.27M and cash from operations negative $1.17M.”
“Operating income was negative $1.26M and cash from operations negative $1.16M.”
“Operating income was negative $1.66M and cash from operations negative $1.59M.”
“Operating income was negative $1.89M and cash from operations negative $1.95M.”
“Operating income was negative $1.11M and cash from operations negative $0.99M.”
Focus on capital allocation by executing equity transactions including warrant exercises and private placements to support liquidity.
Newly stated in 2026-Q2. Management disclosed equity transactions including warrant exercise inducement offers and unregistered sales of equity securities in July 2026 to address capital allocation. No prior quarters mention this priority, so trajectory is newly initiated.
“Entered into warrant exercise inducement offer letters and unregistered sales of equity securities.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 0.99x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.